Comparative trial of two dosages of zalcitabine in zidovudine- experienced children with advanced human immunodeficiency virus disease

Pediatric Infectious Disease Journal

Volumn 16, Issue 6, 1997, Pages 623-624

  Spector, Stephen A ^a   Blanchard, Suzette ^b   Wara, Diane W ^c   Oleske, James M ^d   McIntosh, Kenneth ^e   Hodes, David ^f   Dankner, Wayne M ^a   Salgo, Miklos ^g   McNamara, James ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL OF NEW JERSEY   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g HOFFMANN LA ROCHE INC   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Human immunodeficiency virus disease; Zalcitabine

Indexed keywords

ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ADOLESCENT; ANTI-HIV AGENTS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; INFANT; MALE; ZALCITABINE; ZIDOVUDINE;

EID: 0030919475     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199706000-00015     Document Type: Article

References (12)

1. Oxtoby MJ. Vertically acquired HIV infection in the United States. In: Pizzo PA, Wilfert CM, eds. Pediatric AIDS. Baltimore: Williams & Wilkins, 1994:3-20.
2. Quinn TC, Ruff A, Halsey N. Special considerations for developing nations. In: Pizzo PA, Wilfert CM, eds. Pediatric AIDS. Baltimore: Williams & Wilkins, 1994:31-49.
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
4. Chadwick EG, Nazareno LA, Nieuwenhuis TJ, et al. Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. J Infect Dis 1995;172:1475-9.
5. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected,adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
6. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118:762-9.
7. Devineni D, Gallo JM. Zalcitabine: clinical pharmacokinetics and efficacy. Clin Pharm 1995;28:351-60.
8. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994;330:657-62.
9. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
10. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995;122:24-32.
11. Pizzo PA, Butler K, Balis F, et al. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990;117:799-808.
12. Bakshi S, Britto P, Capparelli E, et al. Evaluation of pharmacokinetics, safety, tolerance and activity of combination of zalcitabine and zidovudine (ZDV) in stable, ZDV-treated, pediatric patients with HIV infection. J Infect Dis 1997;175: 1039-50.